Premium
Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous‐cell carcinoma in India
Author(s) -
Ralhan Ranju,
Arora Sonia,
Chattopadhyay Tushar Kant,
Shukla Nootan Kumar,
Mathur Meera
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(20000315)85:6<791::aid-ijc9>3.0.co;2-k
Subject(s) - antibody , serology , biology , gene mutation , malignancy , cancer research , esophageal cancer , gene , population , gene product , mutation , immune system , exon , carcinoma , cancer , immunology , medicine , gene expression , genetics , environmental health
Esophageal cancer (EC) in the Indian population presents in advanced stages with poor prognosis and warrants the identification of a non‐invasive marker for early detection and better prognostic assessment. We have previously reported high prevalence of p53 protein accumulation in esophageal squamous‐cell carcinomas (ESCCs). The present study was designed to determine (i) if esophageal cancer patients elicit a humoral immune response to intra‐tumoral p53 protein accumulation and (ii) their relationship with p53 gene mutations. The goal was to compare the cellular events, p53 protein accumulation and gene mutations with the presence of serum anti‐p53 antibodies (p53‐Abs) and to assess the utility of serological p53‐Ab analysis as a surrogate marker for p53 alterations in esophageal cancer. A high prevalence of circulating p53‐Abs was observed in 36 of 60 (60%) ESCC patients. In a subset of 44 ESCCs, exons 5–9 of the p53 gene were examined for mutations by PCR and direct sequencing of PCR products. Mutational data have been correlated with p53‐Abs and p53 protein accumulation in ESCCs. Circulating p53‐Abs in ESCC patients were significantly associated with intra‐tumoral p53 protein accumulation ( p =0.0005). A strong correlation observed between humoral immune response against p53 protein, missense gene mutations and protein accumulation warrants the application of serological p53‐Abs as a non‐invasive surrogate marker in screening high‐risk populations for early detection of malignancy. Int. J. Cancer 85:791–795, 2000. © 2000 Wiley‐Liss, Inc.